Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Péter L. Lakatos"'
Autor:
Péter Bacsur, Tamás Resál, Patrícia Sarlós, Ákos Iliás, Liza Dalma Sümegi, Diána Kata, Anett Dávid, Bernadett Farkas, Emese Ivány, Anita Bálint, Zsófia Bősze, Anna Fábián, Renáta Bor, Zoltán Szepes, Waqqas Afif, Talat Bessissow, Klaudia Farkas, Péter L. Lakatos, Tamás Molnár
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: The usability of subcutaneous vedolizumab (s.c. VDZ) treatment in inflammatory bowel diseases (IBD; ulcerative colitis (UC), Crohn’s disease (CD)) has been proven via clinical trials while real-world data collection is ongoing. Objectiv
Externí odkaz:
https://doaj.org/article/c22a45855e894d3eb5843d9997f140aa
Autor:
Katalin Lorinczy, Márk Juhász, Ágnes Csontos, Bálint Fekete, Orsolya Terjék, Péter L. Lakatos, Pál Miheller, Dorottya Kocsis, Sarolta Kárpáti, Zsolt Tulassay, Tamás Zágoni
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 105, Iss 4, Pp 187-193
Introduction and objectives: coeliac disease (CD) and its cutaneous manifestation, dermatitis herpetiformis are both (DH) gluten-sensitive diseases. Metabolic bone disease is common among patients with CD, even in asymptomatic forms. Data are scarce
Externí odkaz:
https://doaj.org/article/b74340ab49c64e8382fa2721d00fd392
Autor:
Laszlo J. Barkai, Lorant Gonczi, Fruzsina Balogh, Dorottya Angyal, Klaudia Farkas, Bernadett Farkas, Tamas Molnar, Tamas Szamosi, Eszter Schafer, Petra A. Golovics, Mark Juhasz, Arpad Patai, Aron Vincze, Patricia Sarlos, Alexandra Farkas, Zsolt Dubravcsik, Tamas G. Toth, Hajnal Szekely, Pal Miheller, Peter L. Lakatos, Akos Ilias
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Long-term data on ustekinumab in real-life Crohn’s disease patients are still missing, though randomized controlled trials demonstrated it as a favorable therapeutic option. We aimed to evaluate ustekinumab's clinical efficacy, drug sustai
Externí odkaz:
https://doaj.org/article/18a9d3318eab411daa58056039b17d6c
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Current therapeutic strategies for inflammatory bowel disease (IBD) have reached a plateau in the rates of response and/or remission achieved with a single therapeutic agent. Consequently, the advanced combination therapy (ACT) strategy has emerged a
Externí odkaz:
https://doaj.org/article/0b3128bbd95445dc9d6a763958045b24
Autor:
Panu Wetwittayakhlang, Christine Verdon, Michael Starr, Gustavo Drügg Hahn, Petra A. Golovics, Talat Bessissow, Waqqas Afif, Gary Wild, Alain Bitton, Peter L. Lakatos
Publikováno v:
The Turkish Journal of Gastroenterology, Vol 34, Iss 6, Pp 603-610 (2023)
Externí odkaz:
https://doaj.org/article/7b44bebf7a8041698455c9eeeac1543d
Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary
Autor:
Livia Lontai, Zsuzsanna Kürti, Lorant Gonczi, Nóra Komlódi, Fruzsina Balogh, Ákos Iliás, Peter L. Lakatos
Publikováno v:
The Turkish Journal of Gastroenterology, Vol 34, Iss 5, Pp 508-515 (2023)
Externí odkaz:
https://doaj.org/article/e352e9d55d57433f9130d57bf132fa08
Autor:
Krisztina B, Gecse, Péter L, Lakatos
Publikováno v:
Nature reviews. Gastroenterologyhepatology. 14(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d308483d4a57793b6a8d2c0462ad5f0e
https://pubmed.ncbi.nlm.nih.gov/28074074
https://pubmed.ncbi.nlm.nih.gov/28074074
Autor:
Michael D, Mandel, Mandel D, Michael, Anita, Bálint, Barbara D, Lovász, László, Gulácsi, Bálint, Strbák, Petra A, Golovics, Klaudia, Farkas, Zsuzsanna, Kürti, Blanka K, Szilágyi, Anna, Mohás, Tamás, Molnár, Péter L, Lakatos
Publikováno v:
The European Journal of Health Economics. 15:121-128
To assess work disability (WD) rates in an inflammatory bowel disease (IBD) cohort involving patients with Crohn's disease (CD) or ulcerative colitis (UC) cohort and to identify possible clinical or demographic factors associated with WD. To our know
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a1a000e7b51e20901e9325c1eae1ba
https://doi.org/10.1007/s10198-014-0603-7
https://doi.org/10.1007/s10198-014-0603-7
Autor:
Debora Garza-Hernandez, Maricruz Sepulveda-Villegas, Jose Garcia-Pelaez, Raul Aguirre-Gamboa, Peter L. Lakatos, Karol Estrada, Manuel Martinez-Vazquez, Victor Trevino
Publikováno v:
BMC Genomics, Vol 23, Iss 1, Pp 1-14 (2022)
Abstract Background Crohn’s disease is one of the two categories of inflammatory bowel diseases that affect the gastrointestinal tract. The heritability estimate has been reported to be 0.75. Several genes linked to Crohn’s disease risk have been
Externí odkaz:
https://doaj.org/article/98a73c7a785c461e81087f23fb56386d
Publikováno v:
Case Reports in Gastroenterology, Vol 16, Iss 1, Pp 116-121 (2022)
Crohn’s disease (CD) and Lynch syndrome (LS) are two different entities, yet both are associated with increased risk of colorectal cancer (CRC). We present the case of a young female patient in long-standing remission of her ileocolonic luminal CD,
Externí odkaz:
https://doaj.org/article/b833245b87a347f293adcbcbfabdc3be